Dihexa vs PE-22-28: Next-Generation Nootropic Peptides Compared

Introduction#

Dihexa and PE-22-28 represent two of the most discussed next-generation nootropic peptides in research communities. Neither has been tested in humans, and both operate through mechanisms fundamentally different from established nootropic peptides like Semax and Selank. What makes them noteworthy is the novelty of their targets: Dihexa works through the hepatocyte growth factor (HGF) / c-Met receptor system, while PE-22-28 blocks TREK-1 two-pore domain potassium channels. Both pathways are relatively unexplored in nootropic pharmacology.

This comparison examines their mechanisms, evidence quality, safety profiles, and practical considerations. The key context for this comparison is that both compounds are strictly preclinical -- all claims about cognitive effects are based on animal models, and the translation of these findings to human cognition is uncertain.

Mechanism of Action Comparison#

Dihexa: HGF/c-Met Synaptogenesis#

Dihexa (PNB-0408, N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a small oligopeptide derived from angiotensin IV. It was developed at Washington State University by the research group of Joseph Harding and John Wright, who were studying the cognitive effects of angiotensin IV and its analogs.

The mechanism centers on hepatocyte growth factor (HGF) and its receptor c-Met. Dihexa binds to HGF with high affinity and potentiates HGF's ability to activate c-Met at concentrations far below normal thresholds. The downstream effects include:

• Synaptogenesis: Formation of new synaptic connections in hippocampal neurons, driven by c-Met-mediated activation of PI3K/AKT and MAPK/ERK signaling cascades
• Spinogenesis: Growth of new dendritic spines, the structural substrate for excitatory synaptic transmission
• Neurotrophic support: In cell-based neurotrophic assays, Dihexa demonstrated potency approximately seven orders of magnitude greater than BDNF

The HGF/c-Met pathway is distinct from the BDNF/TrkB and NGF/TrkA pathways targeted by most nootropic peptides. HGF is primarily known as a morphogen and motogen involved in organ development, wound healing, and tissue regeneration. Its role in the adult brain involves supporting neuronal survival, promoting synaptic plasticity, and facilitating neurogenesis -- functions that make it a plausible target for cognitive enhancement.

PE-22-28: TREK-1 Channel Blockade#

PE-22-28 (Gly-Val-Ser-Trp-Gly-Leu-Arg) is a synthetic 7-amino acid peptide derived from spadin, itself an endogenous peptide released by proteolytic processing of sortilin (neurotensin receptor-3). PE-22-28 was identified through analysis of spadin's active degradation fragments in blood and optimized for enhanced potency and stability.

The mechanism centers on TREK-1, a two-pore domain potassium (K2P) channel widely expressed in the central nervous system. TREK-1 channels are "leak" channels that maintain resting membrane potential and regulate neuronal excitability. By blocking TREK-1, PE-22-28:

• Increases neuronal excitability: Reduces potassium efflux, depolarizing neurons toward firing threshold
• Enhances serotonergic transmission: TREK-1 is expressed on serotonergic neurons in the dorsal raphe nucleus; its blockade increases serotonin release
• Promotes neurogenesis: TREK-1 knockout mice show increased hippocampal neurogenesis, and PE-22-28 recapitulates this effect pharmacologically within 4 days of treatment
• Induces synaptogenesis: TREK-1 blockade promotes dendritic growth and synaptic connection formation

PE-22-28 inhibits TREK-1 with an IC50 of 0.12 nM, making it approximately 300-500 times more potent than spadin. It also has a substantially longer duration of action (approximately 23 hours vs. 7 hours for spadin), attributed to its improved metabolic stability.

Key Mechanistic Differences#

The mechanistic distinction is significant: Dihexa promotes structural synaptic plasticity through growth factor signaling (building new connections), while PE-22-28 modulates functional neuronal properties through ion channel blockade (changing how existing neurons fire). These are complementary rather than competing mechanisms.

Research Evidence Comparison#

Dihexa Evidence#

Dihexa's evidence base rests primarily on publications from the Harding/Wright group at Washington State University:

Cognitive restoration in aged rats. Dihexa restored spatial memory performance in aged rats (24 months) to levels comparable to young rats (4 months) in Morris water maze tasks. The compound was effective when administered orally, demonstrating CNS penetration through oral dosing.

Scopolamine reversal. Dihexa reversed cognitive deficits induced by scopolamine (an anticholinergic agent) in rodent models, suggesting relevance to cholinergic aspects of cognitive impairment.

In vitro synaptogenesis. In hippocampal neuron cultures, Dihexa promoted synapse formation at picomolar concentrations, providing cellular-level evidence for its cognitive mechanism.

Oral bioavailability. Pharmacokinetic studies demonstrated approximately 38% oral bioavailability and blood-brain barrier penetration, unusual for a peptide-based compound and attributable to Dihexa's small size (504.66 Da) and hydrophobic modifications.

The retraction issue. A 2014 publication (McCoy et al., Journal of Pharmacology and Experimental Therapeutics) was retracted due to concerns about data fabrication. While other publications from the group remain intact, the retraction introduces uncertainty about the reliability of some mechanistic claims and demands particular caution in interpreting the overall evidence base.

PE-22-28 Evidence#

PE-22-28's evidence comes primarily from French research groups associated with its development:

TREK-1 pharmacology. PE-22-28 inhibits TREK-1 with an IC50 of 0.12 nM, as determined by electrophysiology in HEK293 cells expressing human TREK-1. This high potency has been independently confirmed and represents a well-characterized pharmacological property.

Antidepressant behavioral effects. In the forced swimming test, PE-22-28 reduced immobility time comparably to the SSRI fluoxetine. In the novelty suppressed feeding test, PE-22-28 reduced latency to feed, an effect that requires chronic antidepressant treatment with SSRIs but occurred after acute PE-22-28 administration.

Rapid neurogenesis. PE-22-28 treatment induced hippocampal neurogenesis after only 4 days, as measured by BrdU incorporation and doublecortin staining. This is substantially faster than the 2-3 weeks typically required for SSRIs to induce neurogenesis.

Duration of action. Behavioral effects of PE-22-28 persisted for approximately 23 hours following a single injection, compared to 7 hours for spadin. This extended duration reflects improved resistance to peptidase degradation.

Limitations. PE-22-28 has not been directly tested in cognitive paradigms such as water maze, novel object recognition, or working memory tasks. Its cognitive potential is inferred from TREK-1 knockout mouse phenotypes (enhanced memory) and from neurogenesis data rather than direct cognitive testing.

Evidence Quality Comparison#

Side Effect and Safety Comparison#

Dihexa Safety Considerations#

The primary safety concern for Dihexa is specific to its mechanism. HGF/c-Met signaling is a well-established oncogenic pathway:

• c-Met is amplified or overexpressed in multiple cancers (gastric, lung, renal, hepatocellular)
• HGF/c-Met activation promotes tumor cell proliferation, survival, invasion, and metastasis
• c-Met inhibitors are FDA-approved cancer drugs (cabozantinib, crizotinib, capmatinib)

A compound that potentiates HGF/c-Met signaling raises theoretical concerns about promoting tumor growth or transformation with chronic use. It is important to note that this concern is entirely theoretical -- no oncological adverse effects have been reported in the limited preclinical studies -- but the biological plausibility is high enough to warrant serious consideration.

Additional safety unknowns include long-term effects on organ systems where HGF/c-Met signaling plays regulatory roles (liver, kidney, cardiovascular system), potential reproductive toxicity, and effects in individuals with pre-existing neoplastic conditions.

PE-22-28 Safety Considerations#

PE-22-28's safety profile is less burdened by mechanism-specific concerns:

• TREK-1 channels are expressed throughout the body (brain, heart, vasculature, gastrointestinal tract), so systemic TREK-1 blockade could theoretically affect cardiovascular function, pain sensation, and gastrointestinal motility. However, TREK-1 knockout mice are viable and generally healthy, suggesting that complete loss of TREK-1 function is tolerated.
• TREK-1 knockout mice show increased seizure susceptibility to kainate and ischemia-induced epileptic events. Whether pharmacological TREK-1 blockade (which is partial and reversible, unlike genetic knockout) carries seizure risk at therapeutic doses is unknown.
• No oncological concerns specific to the TREK-1 blockade mechanism have been identified.
• No chronic toxicity studies have been published.

Safety Comparison Summary#

Practical Considerations#

Availability and Formulation#

Both Dihexa and PE-22-28 are available only as research chemicals from peptide suppliers. Neither has a pharmaceutical formulation, standardized purity requirements, or GMP manufacturing standards commonly applied to approved drugs. Quality control and purity verification are entirely the responsibility of the researcher.

Administration Route#

Dihexa has a notable advantage in practical administration: its demonstrated oral bioavailability (approximately 38%) means it can be taken by mouth with meaningful CNS exposure. This is unusual for peptides, which are typically degraded in the gastrointestinal tract. Dihexa's oral activity is attributed to its small size, modified N-terminus (hexanoic acid cap), and hydrophobic character.

PE-22-28's in vivo studies have used intraperitoneal injection. Oral bioavailability has not been characterized, and the compound's heptapeptide structure (773.89 Da) makes oral activity less likely than for the smaller Dihexa (504.66 Da), though not impossible given its modified sequence.

Stability and Handling#

Dihexa is relatively stable due to its non-natural modifications (N-hexanoic acid cap, aminohexanoic amide C-terminus), which protect it from typical peptidase degradation.

PE-22-28 was specifically designed for improved stability over spadin, with a duration of action of approximately 23 hours compared to spadin's 7 hours. However, detailed stability data under various storage conditions has not been published for either compound.

Key Differences Summary#

• Target pathway: Dihexa activates a growth factor receptor (HGF/c-Met); PE-22-28 blocks an ion channel (TREK-1)
• Primary effect: Dihexa promotes synaptogenesis (structural connectivity); PE-22-28 promotes neurogenesis and neuronal excitability (functional changes)
• Cognitive data: Dihexa has been directly tested in cognitive paradigms; PE-22-28's cognitive potential is inferred from antidepressant tests and TREK-1 KO phenotypes
• Oral bioavailability: Dihexa demonstrates 38% oral bioavailability; PE-22-28 is uncharacterized orally
• Safety concerns: Dihexa raises oncological concerns via HGF/c-Met; PE-22-28 raises seizure threshold concerns via TREK-1 blockade
• Evidence integrity: Dihexa has a retracted key publication; PE-22-28 does not
• Mood effects: PE-22-28 has demonstrated antidepressant effects; Dihexa has not been tested in mood paradigms

Conclusion#

Dihexa and PE-22-28 both represent genuinely novel approaches to nootropic pharmacology, targeting pathways (HGF/c-Met and TREK-1, respectively) that are largely unexplored in cognitive enhancement research. Their mechanisms are complementary rather than competitive, addressing different aspects of neural plasticity: Dihexa promotes the structural formation of new synaptic connections, while PE-22-28 enhances neuronal excitability and drives neurogenesis.

The critical context for both compounds is their preclinical status. Neither has been tested in humans, and both carry significant unknowns -- Dihexa with its retracted publication and oncological pathway concerns, PE-22-28 with its untested cognitive effects and potential seizure susceptibility. These are not compounds with established safety or efficacy profiles; they are research tools that have generated interesting preclinical data.

For researchers evaluating these compounds, Dihexa offers more direct cognitive enhancement data and the practical advantage of oral bioavailability, but at the cost of greater mechanistic safety concerns and a compromised publication record. PE-22-28 offers a cleaner evidence base and a well-characterized pharmacological target, but its cognitive effects remain inferential rather than directly demonstrated.

Both compounds would benefit significantly from independent replication, chronic safety studies, and -- if warranted by safety data -- carefully designed early human studies. Until such data exists, conclusions about their relative cognitive enhancement potential in humans remain speculative.

For context on how these next-generation nootropics compare to established compounds, see our guides on best nootropic peptides and Selank vs Semax. For information on combining cognitive peptides, see our guide on nootropic peptide stacking.

Further Reading#

• Dihexa Overview and Research Guide
• Dihexa Side Effects
• Dihexa Dosing Protocols
• PE-22-28 Overview and Research Guide
• PE-22-28 Side Effects
• PE-22-28 Dosing Protocols